Cancer Genetics, Inc. Launches New Genetic Test For Cervical Cancer Management
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RUTHERFORD, N.J.--(BUSINESS WIRE)--Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, launched its proprietary cervical cancer test and is marketing the molecular product globally through its network of distribution partners. Cervical cancer is the second most common cancer in women worldwide, with 500,000 new cases annually and almost 80% of cases occurring in developing countries.
Help employers find you! Check out all the jobs and post your resume.
RUTHERFORD, N.J.--(BUSINESS WIRE)--Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, launched its proprietary cervical cancer test and is marketing the molecular product globally through its network of distribution partners. Cervical cancer is the second most common cancer in women worldwide, with 500,000 new cases annually and almost 80% of cases occurring in developing countries.
Help employers find you! Check out all the jobs and post your resume.